Physician profile
Jason Reina
NPI 1548236391
$8,407.88
in general payments reported to CMS, 2019-2025
36 companies · $1,820 in 2025
The $1,820 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $411 · 2021: $1,177 · 2022: $1,346 · 2023: $1,489 · 2024: $1,329 · 2025: $1,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,638.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,065.26 | 2019-2025 | |
| Celgene Corporation | $696.46 | 2021-2024 | Zeposia |
| Genzyme Corporation | $518.11 | 2022-2025 | |
| Pfizer INC. | $423.01 | 2019-2025 | |
| Qol Medical, LLC | $401.45 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $337.79 | 2019-2025 | Entyvio |
| Celltrion USA INC. | $330.21 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $290.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $278.74 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $255.64 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $208.80 | 2019-2023 | |
| Janssen Biotech, INC. | $207.51 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $144.22 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $141.71 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $138.63 | 2021-2022 | |
| Ardelyx, INC. | $137.64 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $91.31 | 2020 | |
| Ironwood Pharmaceuticals, INC | $78.59 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $63.14 | 2022-2023 | Rebyota |
| Ucb, INC. | $52.79 | 2019 | |
| Amgen INC. | $44.61 | 2023 | Avsola, Amjevita |
| Evoke Pharma, INC. | $42.18 | 2021-2022 | |
| Lilly USA, LLC | $35.25 | 2025 | Omvoh |
| Alfasigma USA, INC. | $34.15 | 2020-2022 | |
| Organon LLC | $31.49 | 2023 | Hadlima |
| Aimmune Therapeutics, INC. | $30.72 | 2025 | Vowst, Zenpep |
| Nestle Healthcare Nutrition INC. | $30.59 | 2022 | |
| Fresenius Kabi USA, LLC | $25.84 | 2023 | Idacio |
| Novo Nordisk INC | $21.09 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $18.20 | 2024 | |
| Mauna Kea Technologies, INC. | $16.02 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.25 | 2023 | |
| Allergan, INC. | $11.81 | 2019 | |
| Echosens North America, INC. | $11.25 | 2021 | |
| Shire North American Group INC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Reina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.